Quantum Genomics

PAR: ALQGC

Market Cap€5m

Last Close €0.15

Quantum Genomics is a Paris-based biotechnology company focused on addressing unmet medical needs.

More Quantum Genomics content >

Investment summary

Following the announcement that results from the Phase III FRESH study, investigating the use of firibastat in TRH were non-significant versus placebo, Quantum Genomics has terminated a second, longer-term Phase III trial (REFRESH) in TRH and will stop the development of firibastat in cardiology. The company estimates it will have c €11m after the full discontinuation of cardiology development with which to pursue new opportunities to develop new assets. The company will present the full results from the FRESH study at the American Heart Association congress in November. Our estimates and valuation for Quantum Genomics are under review.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2020A 4.0 (13.1) (14.7) (72.0) N/A N/A
2021A 6.2 (14.9) (15.4) (58.0) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A
Industry outlook

The global market for cardiovascular drugs is considerable; in 2021 the market for hypertension drugs alone was estimated to be worth c US$13bn. Quantum Genomics has already secured seven licensing deals worldwide (worth up to c US$123m) but has not yet signed an agreement in the key US or EU5 regions. We view the signing of a licensing agreement in these regions as key to maximising the commercial impact of the asset.

Last updated on 30/11/2022
Content on Quantum Genomics
Quantum Genomics – Firibastat misses endpoints in Phase III
Healthcare | research Flash note | 28 October 2022
Medicine doctor and stethoscope touching icon heart and diagnostics analysis medical on modern virtual screen interface network connection. Medical technology diagnostics of heart concept
Quantum Genomics – Steady sailing as FRESH readout approaches
Healthcare | research Update | 5 October 2022
Medicine doctor and stethoscope touching icon heart and diagnostics analysis medical on modern virtual screen interface network connection. Medical technology diagnostics of heart concept
Quantum Genomics – A fresh take on cardiovascular medicine
Healthcare | research Initiation | 30 August 2022
Medicine doctor and stethoscope touching icon heart and diagnostics analysis medical on modern virtual screen interface network connection. Medical technology diagnostics of heart concept
View more
Register to receive research on Quantum Genomics as it is published
Share price graph
Balance sheet
Forecast net debt (€m) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (52.5) (94.6) (96.6)
Relative* (55.7) (95.0) (96.5)
52-week high/low €4.4/€0.1
*% relative to local index
Key management
Jean-Philippe Milon CEO
Benoît Gueugnon CFO
Lionel Ségard Founder & Chairman